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We prospectively evaluated 2 postconsolidation strategies, administered according to the mobilization
outcome, in 72 acute myeloid leukemia (AML) ﬁt elderly patients, achieving complete remission after the
ﬁrst high-dose cytarabine-based induction. Autologous stem cell transplantation (ASCT) was performed in
patients collecting 3  106 CD34þ/kg and low-dose gemtuzumab ozogamicin (GO) was performed in poor
mobilizers (collecting <3  106 CD34þ/kg). Fifty-ﬁve patients (76.3%) underwent peripheral blood stem cell
(PBSC) mobilization, after ﬁrst consolidation, and 24 of 55 (44%) collected >3  106 CD34þ cells/kg. Among
the 55 patients eligible for PBSC mobilization, 7 did not receive the planned treatment, 23 were allocated for
ASCT, and 25 were allocated for GO on an intention-to-treat basis. With a median follow-up of 70 months
(range, 24 to 124), 20 of 55 patients are alive, 18 of them in continuous complete remission. The 8-year
overall survival (OS) and disease-free survival (DFS) are, respectively, 35.9% (95% conﬁdence interval [CI]
24% to 49.8%) and 31.2% (95% CI, 21% to 43.8%), median OS and DFS were 22 and 16 months, respectively. In
multivariate analysis, postconsolidation treatment and hyperleukocytosis (WBC > 50,000/mL) signiﬁcantly
predicted OS and DFS, whereas secondary AML was signiﬁcantly associated with a higher relapse rate (83.4%
versus 54% of de novo AML). Patients with hyperleukocytosis had 0% 3-year OS versus the 46% (at 8 years) in
patients without hyperleukocytosis (P ¼ .01); 57% of patients in the GO arm are alive at 8 years, compared
with 25.4% of patients in the ASCT arm, who had an overall relative risk (RR) of death of 2.6 (95% CI, 1.2 to
5.8; P ¼ .02). DFS at 8 years was 45.3% in patients receiving GO, compared with 26% in ASCT arm (RR, 2.1; 95%
CI, 1 to 4.3; P ¼ .05). Our study outlines low feasibility and efﬁcacy of ASCT in elderly AML patients, whereas
postconsolidation with GO appears safe and effective in this unfavorable setting. The study was registered at
Umin Clinical Trial Registry (www.umin.ac.jp/ctr), number R000014052.
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Acute myeloid leukemia (AML) in elderly patients is still
characterized by poor prognosis. Factors related to age,
including poor performance status (PS) and comorbidities,
may negatively affect tolerance to treatment [1].dgments on page 1405.
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14.05.019In this setting, the high frequency of secondary AML,
often associatedwithmultidrug resistance phenotype and/or
unfavorable karyotype, may likewise lower the response rate
and response duration [2]. Despite the introduction of new
drugs, no signiﬁcant improvement has been observed in
recent years in this setting [3]. The intensiﬁcation of
induction with high-dose daunorubicin has been explored,
only in patients under 65 years, with encouraging results [4].
High-dose cytarabine (HD-ARAC) has also been tested as
consolidation treatment in younger patients, but this
approach has been discouraged in the elderly population
[5,6]. The poor outcome in these older patients is generallyTransplantation.
D. Capelli et al. / Biol Blood Marrow Transplant 20 (2014) 1399e14061400characterized by a low complete remission (CR) rate and a
high treatment-related mortality (TRM) rate, but it also
yields an unacceptably high relapse rate. This is not only due
to the adverse biological features of the disease, but also
by the inefﬁcacy (and/or low feasibility) of the post-
consolidation therapy. A large German multicenter trial in
patients ages 16 to 85 years did not show a better outcome
after autologous stem cell transplantation (ASCT), compared
with maintenance therapy [7]. However a number of trials,
including ASCT as postconsolidation strategy in elderly AML
patients, show low percentages of patients receiving this
kind of postconsolidation strategy [8-10].
Gemtuzumab ozogamicin (GO) is an anti-CD33 human-
ized monoclonal antibody, conjugated with calicheamicin
[11]. This antibody has been used at conventional dose
(9 mg/m2) in combination with induction chemotherapy in
AML elderly patients, achieving an overall and relapse-free
survival advantage [12,13]. Conversely, the Hemato-
Oncology Cooperative Hovon Group/Swiss Group for
Clinical Cancer Research (HOVON-SAKK) randomized trial
failed to showa signiﬁcant better outcome, administering GO
at 6 mg/m2 as postconsolidation treatment [13]. The recent
Medical Research Council (MRC) study showed that adding
GO to the induction schedule was associated with a better
outcome, especially in patients with favorable-intermediate
cytogenetic/molecular markers [14].
Except for some preliminary data suggesting the feasi-
bility of GO at very low dose as postconsolidation therapy
[15,16], so far this drug has never been investigated in this
setting. To offer an alternative post-consolidation treatment
to the elderly AML patients, ﬁt for ASCT, failing PBSC mobi-
lization, we designed a post-consolidation schedule with GO
at very low dose, in order to evaluate the feasibility and ef-
ﬁcacy of these two different post-consolidation therapies.
Patients were enrolled in the two treatment arms accordingFigure 1. Flow chart of the study dethe mobilization outcome, and results were analysed on an
intention-to-treat basis.
PATIENTS AND METHODS
This is a phase II prospective study, conducted in ﬁt elderly AML patients
in CR1, after intensive induction therapy, based on the association of idar-
ubicinwith HD-ARAC, as previously reported [17]. Themain objectivewas to
assess feasibility (in terms of safety and efﬁcacy) of 2 postremission stra-
tegies: ASCTand low-dose GO. The primary endpoint was to evaluate overall
survival (OS) in the 2 cohorts; secondary endpoints were treatment-related
mortality (TRM), relapse incidence (RI), and disease-free survival (DFS).
The study was approved by the institutional review board and registered
in the UMIN Clinical Trial Registry (R000014052); all patients gave written
informed consent in accordance with the Helsinki declaration. Among 100
non-M3 AML ﬁt elderly patients, ages >59 years, receiving intensive induc-
tion, 72 achieved CR after induction treatment and 55, who maintained ﬁrst
continuous complete remission (CCR) after ﬁrst consolidation, received ﬁl-
grastim (5 mg/kg per day subcutaneously from day þ1 after the end of
chemotherapy until the last leukapheresis) for PBSC mobilization. Collection
of CD34þ cells and ASCT management were performed as previously
described [18]. A minimum dose of CD34þ cells collected (>3  106/kg) was
required for ASCT. The minimum CD34þ cell dose required for ASCT was
increased from the usual target of 2  106/kg to 3  106/kg because we were
aware of an incomplete or slow hematological recovery in this elderly AML
setting. According to themobilization outcome, patients were analyzed either
in the ASCT arm (CD34þ collection 3  106/kg) or in the GO arm (CD34þ
collection<3  106/kg), regardless of the treatment they actually received on
an intention-to-treat (ITT) basis. The ASCT procedure was performed in
hospitalized patients and the supportive care, including antimicrobial pro-
phylaxis, has been previously described [18]. The ﬁrst 12 patients underwent
a conditioning regimen including melphalan at 120 mg/m2 i.v., associated
with oral busulfan (9.6 mg/kg). However, because of a high incidence of se-
vere mucositis, the protocol was amended replacing the former conditioning
regimen with a BEAM modiﬁed scheme including 140 mg/m2 melphalan i.v.,
associated with bis-chloroethylnitrosourea (BCNU) (300 mg/m2), cytarabine
2400 mg/m2, and etoposide 450 mg/m2 in 9 further patients; patients over
70 years of age received the same schedule with 30% reduction of the drug
dosage.
In patients collecting <3  106/kg CD34þ, not eligible for ASCT, GO was
administered on outpatient basis at 3 mg/m2 i.v., every 28 days for 3months,
followed by 3 infusions at 3-month intervals. The study ﬂowchart is illus-
trated in Figure 1. The main clinical and biological characteristics of the AMLsign and patients’ treatment.
Table 1
Patient and Disease Characteristics in the Autologous and Gemtuzumab
Arms
Gemtuzumab Autologous
Transplantation
P Value
Gender .04
Male 17 9
Female 8 14
Karyotype .15
Favourable-intermediate 4-14 0-11
Unfavourable 5 8
Primary AML 18 15 .60
Secondary AML 7 8
WBC count at diagnosis .34
<50,000/mL 22 22
50,000/mL 3 1
Age .73
<70 yr 14 14
70 yr 11 9
Median (range) 68 (61-76) 67 (60-77)
FDI* .16
0 18 12
>0 7 11
Sorror HCT-CIy score .94
0-2 18 17
>2 5 5
WBC indicates white blood cell.
* Malfuson et al. [24].
y Sorror et al. [25].
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Terminology Criteria for Adverse Events to evaluate extrahematological
toxicities in the 2 postconsolidation arms.
Statistical Methods
Response criteria and treatment outcomes were deﬁned according to
the Cheson criteria [19]. Two-tailed Fisher exact test was performed to
analyze differences between the ASCT and GO arms in terms of age (cut-off
>70 years), cytogenetic risk [20-23],WBC count (cut-off>50,000/mL), World
Health Organization PS, diagnosis of secondary/de novo AML, French
decisional index (FDI) [24], and Sorror hematopoietic cell trans-
plantationecomorbidity index (HCT-CI) score [25]. Based on the ITT criteria,
we assessed the outcomes in the 2 arms, according to the above-mentioned
variables, the kind of postremission, and the dose of CD34þ cells, deﬁning
super and normal mobilizers as those patients collecting more or less than
7.1  106/kg CD34þ cells, respectively. A landmark analysis was performed,
computing survival (OS and DFS) or relapse (RI) from the end of ﬁrst
consolidation; OS, RI and DFS were estimated by the Kaplan-Meier method
[26]. A log rank test was performed to compare survival probabilities, ac-
cording to age, the postconsolidation arm, and disease characteristics. The
results are reported using 2-sided P values and 95% conﬁdence intervals (CI).
All factors identiﬁed at univariate analysis with a P value <.10 were entered
into the multivariate analysis, where relative risks (RRs) and 95% CIs were
calculated by using the multivariate Cox regression analysis. Data were
analyzed using SPSS 18.0 software.
RESULTS
Mobilization
Fifty-ﬁve patients in CR1 underwent PBSC mobilization
after consolidation and 24 (44%) collected >3  106 CD34þ
cells/kg and 31 were poor mobilizer (CD34þ harvest
<3  106/kg). Seven patients dropped out of the study, upon
the decision of the physician and patient, and did not receive
the planned postconsolidation treatment: 4 underwent
allogeneic stem cell transplantation from an HLA-identical
sibling and 3 received intermediate-dose cytarabine. There-
fore, 48 of 55 patients in CCR1 were biologically allocated
into the 2 arms of postconsolidation therapy, according to
the mobilization outcome.
In detail: among the 24 patients who successfully mobi-
lized, 1 received an allogeneic transplant from an HLA-
matched sibling (and was excluded from the analysis);among the 23 scheduled for ASCT (ITT), 2 relapsed before
ASCT and 21 received ASCT (20 in CR, 1 in early relapse).
Among the 31 poor mobilizers, 3 underwent allogeneic
transplantation and 3 received alternative chemotherapy
(because of temporary GO unavailability); therefore 25
patients were scheduled (ITT) for GO as postconsolidation
therapy; 5 of them did not receive GO because of early
relapse, low PS, or persistent aplasia (Figure 1).
In summary, 48 of 55 patients after consolidation and
mobilization, were evaluated in the 2 arms (23 in ASCT and
25 in GO) on an ITT basis. Main patient characteristics (age,
cytogenetic risk, secondary disease, hyperleukocytosis,
World Health Organization PS, FDI, and Sorror HCT-CI score)
were equally distributed among the 2 treatment arms
(Table 1). Time to the ITT consolidation was not different
between the 2 cohorts.
Toxicity
ASCT arm
Twenty-one patients received ASCT at a median time of
4 months from diagnosis and 1.5 months from the start of
landmark analysis. Overall, 5 patients died from procedure-
related causes: 1 sudden death in aplasia, 2 from sepsis, 1
from acute respiratory distress syndrome, and 1 from CMV
infection, accounting for a 19% 100 day-TRM and 25% 6-
month TRM. Median duration of severe neutropenia (abso-
lute neutrophil count <100/mL) was 5 days (range, 4 to
8 days). Hematological reconstitution was evaluable in 15
patients (71.5%), who showed a prompt and complete
engraftment, with a median recovery of absolute neutrophil
count >1500/mL and platelet >50,000/mL within 11 (range, 9
to 20) and 18 days (range, 14 to 60), respectively. Twelve
patients achieved a >100,000/mL platelet count within a
median of 21 days (range, 14 to 60), whereas 3 patients in CR
relapsed early within 5 months from ASCT. A median of 2
(range, 0 to 8) red blood cell and 3 (range, 0 to 11) platelet
units were transfused. Median duration of fever >38C and
antibiotic treatment were 1 (range, 0 to 21) and 8 (range, 0 to
31) days, respectively. Median duration of hospitalization
was 24 days (range, 17 to 45). The main extrahematological
toxicity was represented by infections, with 7 (33.3%) grades
III and IV, 3 (14.3%) grade V episodes (the latter observed
after conditioning with busulfan-melphalan), and gastroin-
testinal mucositis in 4 patients (19%) as shown in Table 2.
GO arm
Twenty patients received GO consolidation at a median
time of 4 months from diagnosis and 1.5 months from the
start of landmark analysis. Hematological and extra-
hematological toxicities were analyzed after 120 GO courses.
Infusion-related adverse events, consisting of fever, chills,
and transient hypotension, were observed in 6 cases, all
grades I and II. Grades III and IV hematological toxicities were
common, with 9 cases of neutropenia and 8 cases of
thrombocytopenia, all recovering by day 30. Transient liver
enzymes elevationwas observed in 5 cases, only 1 of grade III
to IV, all reversible. We did not observe any case of veno-
occlusive disease. No toxic deaths were observed. Hemato-
logical and extrahematological toxicities are shown in
Table 3.
Outcome
Twenty of the 55 patients eligible for PBSC mobilization
after ﬁrst consolidation are still alive, with a median follow-
up of 70 months (range, 24 to 124); 18 of them in CCR.
Table 2
Hematological and Extrahematological Toxicity in Patients Receiving ASCT
(n ¼ 21)
Toxicity Value, median
(range)
Grades III-V
Hematological
Duration of neutropenia
ANC < 100/mL 5 (4-8)
Transfusional need
RBC units 2 (0-8)
PLT units 3 (0-11)
Days with fever >38C 1 (0-21)
Duration of i.v. ATB 8 (0-31)
Hematological recovery
(in 71.5% of patients)
ANC > 1500/mL 11 (9-20)
PLT > 50,000/mL 18 (14-60)
PLT > 100,000/mL 21 (14-60)
Duration of hospitalization, d 24 (17-45)
Extrahematological
Gastrointestinal
Mucositis 4
Hepatic -
Genitourinary 1
Cutaneous 1
Infectious 10 (3 grade V)
Neurological 1
Cardiovascular 1
Other -
ANC indicates absolute neutrophil count; RBC, red blood cell; PLT, platelet;
ATB, antibiotics.
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(n ¼ 25) arms, on the ITT basis, the median follow-up was
65.1 months in the former arm and 85.8 months in the latter.
The overall 8-year OS and DFS are, respectively, 35.9% (95%
CI, 24% to 49.8%) and 31.2% (95% CI, 21% to 43.8%). Median OS
and DFS are 22 and 16 months, respectively. (Figure 2A,B).
Twelve patients belonging to ASCT arm died of leukemia,
2 before ASCTand 10 in relapse after ASCTwithin 20months;
5 after busulfan melphalan and 5 after BEAM; (BCNU
300 mg/sm, Etoposide 450 mg/sm, Cytarabine 2400 mg/sm,
140 mg/sm Melphalan) 5 died of TRM, all after busulfan
melphalan; and 6 are alive and in CR, 2 after busulfan
melphalan and 4 after BEAM.
Among the GO arm, 11 patients died of leukemia and 14
are alive; 12 of them in CR; no toxic deaths have been
observed. Thirteen patients relapsed, 4 within 5 months and
9 after 1 year (range,12 to 37months); GO retreatment led to
a second long-lasting CR in 3 patients (11,17, and 21months).
To compare the efﬁcacy of the 2 postconsolidation treat-
ments, we performed a landmark analysis (Table 4), adjusted
for the main prognostic factors including cytogenetics, type
of AML (de novo versus secondary AML), presence of
hyperleukocytosis at diagnosis (WBC > 50,000/mL), age,
performance status, FDI, and Sorror HCT-CI score. Patient andTable 3
Hematological and Extrahematological Toxicities Observed in Patients
after GO Infusions (n ¼ 20 patients and 120 infusions)
Toxicity Grade III-IV
n (%)
Hematological
Thrombocytopenia 8 (6.6%)
Neutropenia 9 (7.5%)
Extrahematological
Hepatic 1 (.08%)
Infusion-related symptoms 0disease characteristics were equally distributed among the 2
treatment arms (Table 1). After 8 years, 57% of patients in the
GO arm were alive, compared with 25.4% of patients in the
ASCT arm (P ¼ .01). In the ASCT arm, the patients mobilizing
more and less than 7.1106/kg CD34þ cells were categorized
as “super” and “normal” mobilizers [27]. Super mobilizers
had a 25% 8-year OS, compared with 27.3% of normal mobi-
lizers (P ¼ not signiﬁcant). DFS at 8 years was 45.3% in pa-
tients receiving GO, compared with 26.1% (95% CI, 12.5% to
46.6%; P ¼ .03) in the ASCT arm (Figure 3), without statistical
differences between normal and super mobilizers and the 2
conditioning regimens (data not shown). Finally, RI was
54.7% in GO arm and 64% in ASCT arm: 67.3% in normal
mobilizers and 58.3% in super mobilizers, without signiﬁcant
differences between the 2 arms. Patients receiving busulfan
melphalan and BEAM conditioning had 63% and 56% RI,
respectively (P ¼ not signiﬁcant).
Patients with secondary AML had a 26.7% 8-year OS,
compared with 49% of those with de novo AML (P ¼ .10); the
RI was 83.4% in secondary AML versus 54% in de novo AML
(P ¼ .01). All patients with hyperleukocytosis died within
15 months, whereas 40.7% of patients without hyper-
leukocytosis were still alive after 8 years (P ¼ .008). The 13
patients with an unfavorable karyotype had a 30.8% 8-year
OS, compared with 49.2% of those with favorable or inter-
mediate karyotype (P ¼ .11).
The factors selected at the univariate analysis, (1) type of
postconsolidation treatment, with categories for normal and
super mobilizer, (2) hyperleukocytosis, (3) secondary or de
novo AML, and (4) cytogenetic risk, were entered a multi-
variate Cox regression model (Table 5). The post-
consolidation treatment and hyperleukocytosis were the
only signiﬁcant predictors for OS. Both normal and super
mobilizer patients, receiving ASCT, had a higher risk of death
(RR, 2.6; 95% CI, 1.2 to 5.8; P ¼ .02) compared with patients
receiving GO. Patients with hyperleukocytosis had a 4.2 (95%
CI, 1.3 to 13.5) (P ¼ .01) RR of death, compared with patients
with WBC < 50,000/mL.
The postremission treatment and hyperleukocytosis also
signiﬁcantly inﬂuenced DFS, without any effect of the dose of
CD34þ cells collected and reinfused. Patients who under-
went transplantation had 26% DFS at 8 years with a 2.1 (95%
CI, 1 to 4.3) RR of relapse or death, in comparison with GO
patients (P ¼ .05), with 45.3% DFS at 8 years. Patients with
hyperleukocytosis had a 0% DFS at 15 months with a 3.4 RR
(95% CI, 1.1 to 10) of relapse or death when compared with
patients with WBC < 50,000/mL, who had 39.7% DFS at
8 years (P ¼ .03).
The diagnosis of secondary AML was the only signiﬁcant
factor predicting relapse in multivariate analysis, with a RR
of 2.45 (95% CI, 1.1 to 5.3) (P ¼ .02) and a cumulative RI of
83.4% at 8 years versus the 54.7% observed in de novo AML
patients.
DISCUSSION
In recent years, no signiﬁcant improvements in the
setting of elderly AML patients have been observed, both for
induction and for consolidation therapy. To improve the
outcome for elderly patients ﬁt for intensive treatment, we
tested both an unconventional induction regimen with
idarubicin amifostine plus HD-ARAC, and a post-
consolidation strategy, adapted to the PBSC mobilization
outcome. The feasibility of the induction regimen had been
previously reported in a preliminary series of 42 AML elderly
patients [28]. Here, we evaluated 55 patients eligible for
Figure 2. (A) Overall survival in 100 AML elderly patients, candidates for postconsolidation therapy, according to ITT criteria. (B) Disease-free survival in 100 AML
elderly patients, candidates for postconsolidation therapy, according to ITT criteria.
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mobilization driven.
In previous randomized trials, the outcomes for elderly
AML patients who achieved CR were similar, regardless the
intensity of postremission treatment [3,29,30].
So far, the main trials exploring low-dose chemotherapy
maintenance in adults have given discordant results [31,32].
The German study showed a 30% 4-year OS in the arm
receiving a second high-dose consolidation treatment
versus 15% observed in patients receiving oral maintenance
with idarubicin and etoposide. Conversely, the French
study showed a similar outcome after 1 or 2 intensive
consolidation courses versus 6 courses of low-dose
cytarabine þ idarubicin, with 2-year OS of 41%, 55%, 58%,
respectively.
ASCT may represent a therapeutic option in AML patients,
and the introduction of PBSC as a source signiﬁcantly low-
ered its toxicity [33], with 5.5% TRM, compared with 12%
observed in patients with bone marrow as a source [34]. In
AML patients, particularly those older than 65 years,Table 4
Landmark Univariate Analysis of DFS and OS
Eight-year OS (95 CI %) P Value Eight
Karyotype .10
Favorable/intermediate 49.2 (31.2-67.4) 42.3
Unfavorable 30.8 (12.7-57.7) 23.1
De novo AML 49 (32.2-66.1) .10 43.8
Secondary AML 26.7 (10.9-51.9) 20
Age .39
<70 yr 48.7 (31.1-66.6) 50
70 yr 33.3 (16.4-56) 20
WBC count at diagnosis .008
<50,000/mL 46 (31.7-61) 39.7
50,000/mL 0 0
PS .7
<2 40.7 (26.6-56.5) 33.9
>1 50 (18.8-81.2) 50
Consolidation regimen .01
Gemtuzumab 57.1 (36.9-75.2) 45.3
ASCT 25.4 (12-46) 26.1
Consolidation regimen .04
Gemtuzumab 57.1 (36.9-75.2) 45.3
ASCT normal mobilizer* 27.3 (10-56.5) 27.3
ASCT super mobilizer* 25 (9-53.2) 25
FDIy .16
0 45.7 (28.3-64.2) 39.6
>0 35.3 (17.3-58.7) 29.4
Sorror HCT-CIz .92
0-2 44.2 (28.7-61) 41.8
>2 40 (16.8-68.7) 20
* Patients are deﬁned as normal and super mobilizers if they collected less or mo
y Malfuson et al. [24].
z As described by Sorror et al. [25].mobilization is poor [35] and some retrospective studies
suggest that AML patients collecting or reinfusing high
numbers of CD34þ cells (super mobilizers) have an increased
risk of relapse [27,36].
In our study, patients mobilizing more than 7.1  106/kg
CD34þ cells had signiﬁcantly reduced OS when compared
with those mobilizing less than 7.1 106/kg CD34þ cells, but
only in univariate analysis. The paucity of the difference and
the low number of patients with this result may explain why
this result was not found in the OS multivariate and DFS
analyses. Furthermore, normal mobilizers had a higher RI in
comparison with super mobilizers, but the difference was
not statistically signiﬁcant. Our data suggest that the most
important factors inﬂuencing the outcome, regardless the
amount of CD34þ cell collected, are the type of post-
consolidation treatment and the characteristics of the dis-
ease (hyperleukocytosis and secondary AML).
To date, the effectiveness of ASCT in AML patients is still
debated [37-39] and some studies suggest that post-
consolidation ASCT in elderly AML patients is feasible only in-year DFS (95% CI) P Value Eight-year RI (95% CI) P Value
.10 .27
(25.5-61.1) 60 (42-75.7)
(8.2-50.3) 69 (43.7-86.5)
(28-61) .08 54.7 (38.3-70) .01
(7.1-45.1) 83.4 (60.8-94.2)
.12 .056
(32.7-67.3) 41.2 (24.7-60)
(8.1-41.5) 79 (56.7-91.5)
.01 .05
(27.2-53.7) 56.8 (41.3-71.1)
75 (30-95.4)
.6 .82
(20.9-49.8) 60 (43.4-74.6)
(18.8-81.2) 57.2 (25-84)
.03 .20
(27-65) 54.7 (35-63)
(12.5-46.6) 64 (42-84)
.10 .39
(27-65) 54.7 (35-63)
(9.8-56.5) 67.3 (37-87.8)
(9-53.2) 58.3 (29.8-82.2)
.19 .16
(23.6-58.2) 55.6 (36.8-73)
(13.2-53.2) 65.3 (41.3-83.4)
.25 .12
(26.8-58.4) 56 (36.2-74.1)
(5.7-50.9) 80 (49-94.3)
re than 7.1  106/kg CD34þ cells, respectively.
Figure 3. Disease-free survival and overall survival in 48 AML patients, according to postremission treatment.
D. Capelli et al. / Biol Blood Marrow Transplant 20 (2014) 1399e14061404a small percentage of patients [8-10]. In our prospective
study, only 24 of the 55 patients in CR1, eligible for mobili-
zation, collected a sufﬁcient number of CD34þ cells. More-
over, we observed a relevant toxicity after ASCT, with 19%
early TRM and early disease recurrences.
Our patients underwent PBSC transplantation; however,
stem cell source (PBSC or bone marrow) might also have
inﬂuenced the outcome; Gorin et al. showed that patients
receiving PBSC had a worse prognosis compared with those
receiving bone marrow [40]. The same author found that
AML patients receiving high amounts of CD34þ cells have
higher RI after ASCT [36], conﬁrming that the so-called
category of super mobilizers represents an adverse risk fac-
tor. Also the European Organisation for Research and Treat-
ment of Cancer - Gruppo Italiano delleMalattie EMatologiche
dell’Adulto (EORTC-GIMEMA) AML10 trial experience
conﬁrmed the correlation between stem cell dose harvest
and incidence of relapse, showing an higher risk of relapse in
patients collecting more than 7  106/kg [27].
Taken together, our results discourage postconsolidation
ASCT in this setting: compared with low-dose GO, post-
consolidation with ASCT is characterized by low feasibility
and high toxicity. Moreover, RI was higher in both normal
and super mobilizers receiving ASCT compared with those in
the GO arm.
Conversely, postconsolidation with very low-dose of GO
appears safe and effective, with a remarkable 46% DFS and
57% OS at 8 years. Multivariate analysis conﬁrmed that GO
was associated with signiﬁcant better outcome, compared
with ASCT (regardless the category of mobilizer, super or
normal); only GO treatment, hyperleukocytosis, and sec-
ondary AML emerged as signiﬁcant factors for outcome,
whereas secondary AML was the only factor inﬂuencing RI.
Other variables, such as age 70 years and PS, and other
composite variables, such as the FDI and the Sorror score, did
not result in signiﬁcant effects on outcome.
Surprisingly, cytogenetics were only nearly signiﬁcant in
the univariate analysis; however, our data could be biased by
the limited number of patients observed in the 2 arms and byTable 5
Landmark Multivariate Analysis of OS, DFS, and RI
OS
RR (95% CI)
P Value
Consolidation regimen .02
Gemtuzumab 1
ASCT 2.6 (1.2-5.8)
WBC count at diagnosis .01
<50,000/mL 1
50,000/mL 4.2 (1.3-13.5)the fact that the mobilization outcome may have selected
patients with different prognoses, although the percentage
of patients with unfavorable cytogenetics and secondary
AML were similar in the 2 arms.
In previous experiences, GO at 6 mg/m2, showed a less
favorable toxicity proﬁle, when administered with chemo-
therapy; a higher incidence of veno-occlusive disease and a
lower hematological tolerance have been observed in the
recent Hemato-Oncology Cooperative Hovon Group/Swiss
Group for Clinical Cancer Research (HOVON-SAKK) trial [14].
Furthermore, this dosage hampered the feasibility of this
approach: only 58% of patients received the 3 planned
consolidation courses, with no survival advantage in com-
parison with untreated patients.
In our experience, repeated doses of GO 3 mg/m2, in CR
patients with low leukemia burden was well tolerated and
allowed optimal compliance to the planned therapy. Grade III
and IV hematological and extrahematological toxicities were
all transient and did not affect dose intensity.
The recent phase III Acute Leukemia French Association
(ALFA)-0701 [13] study evaluated the same dose of GO
(3 mg/m2 with a cumulative dose of 9 mg/m2) during in-
duction and consolidation with an event-free survival and
OS beneﬁt, compared with the control arm. Similar results
have been reported in the Medical Research Council (MRC)
trial AML 16, where a single dose of 3 mg/m2 was ad-
ministered during the ﬁrst and third course of chemo-
therapy [12].
A recent review [41] highlights how GO efﬁcacy may in
someway related to both antibody and daunorubicin dose, as
the survival advantage was observed when low or fraction-
ated doses of GO were administered in association with at
least 60 mg/m2 of daunorubicin, as in the French ALFA-0701
trial.
Our study has several limitations, 1 of which is the low
number of patients evaluable for postconsolidation treat-
ment; however, this realistically reﬂects the low percentage
of ﬁt elderly AML patients eligible for postconsolidation
therapy [8]. The low incidence of hyperleukocytosis (presentDFS
RR (95% CI)
P Value RI
RR (95% CI)
P Value
.05 -
1
2.1 (1-4.3)
.03 -
1
3.4 (1.1-10)
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already validated, but to a lesser extent than cytogenetics, in
previous larger cohorts of AML patients [42].
Another limitation of our study is the lack of data on
molecular markers (such as ﬂt3 or NPM1) that could inﬂu-
ence the outcome after ASCT or GO [15]. Our study was
designed in the premolecular markers era, and the cry-
opreserved DNA and RNA samples to test thesemarkers were
not available.
Finally, the main limitation of our study is the
mobilization-driven randomization; we cannot exclude that
the mobilization success could have selected a more bio-
logically favorable subset of disease in ﬁrst CCR after ﬁrst
consolidation. On the other hand a postinduction randomi-
zation would jeopardize study feasibility because of the low
mobilization rate in elderly AML patients and a subsequent
low adherence to the assigned treatment. The bias of per-
forming landmark analysis in CCR patients in ﬁrst consoli-
dation could be probably counterbalanced by the equal
distribution of patient and disease characteristics in the 2
arms, without signiﬁcant differences between poor and good
mobilizers.
In conclusion, our study suggests that postconsolidation
treatment with GO at very low dose is safer and more
effective than ASCT, and the administration of very low doses
of GO in patients in CR andwith low leukemia burdenmay be
associated with advantages of improved tolerability and
similar efﬁcacy. Nonetheless, these results should be
conﬁrmed by randomized clinical trials in the setting of
postconsolidation treatment.
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